CoChat
Sign Up
Cited by 131

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

APOE-amyloid interaction: Therapeutic targets

Wisniewski, Thomas, Drummond, Eleanor·2020·Neurobiology of Disease
DOI 10.1016/j.nbd.2020.104784PMC PMC7118587
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2020.104784

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Blocking the interaction between apolipoprotein E and PGRMC1 increases amyloid-β clearance from the brain, reduces amyloid-β deposition, and reduces related pathology in Alzheimer animal models.

    “Blocking the interaction between apolipoprotein E and PGRMC1 increases amyloid-β clearance from the brain, reduces amyloid-β deposition, and reduces related pathology in Alzheimer animal models [124].”

    From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [124]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 80

  1. Bertram, 2012, The genetics of Alzheimer’s disease, Prog. Mol. Biol. Transl. Sci., 107, 79, 10.1016/B978-0-12-385883-2.00008-4 · DOI
  2. Brodbeck, 2011, Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors, J. Biol. Chem., 286, 17217, 10.1074/jbc.M110.217380 · DOI · Paper page
  3. Calero, 2000, Apolipoprotein J (clusterin) and Alzheimer’s disease, Microsc. Res. Tech., 50, 305, 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L · DOI
  4. Castano, 1995, Fibrillogenesis in Alzheimer’s disease of amyloid beta peptides and apolipoprotein E, Biochem. J., 306, 599, 10.1042/bj3060599 · DOI · Paper page
  5. Cerf, 2011, High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer’s disease, FASEB J., 25, 1585, 10.1096/fj.10-175976 · DOI · Paper page
  6. Chen, 2012, Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons, J. Biol. Chem., 287, 5253, 10.1074/jbc.M111.276162 · DOI · Paper page
  7. Coppus, 2008, The impact of apolipoprotein E on dementia in persons with Down’s syndrome, Neurobiol. Aging, 29, 828, 10.1016/j.neurobiolaging.2006.12.013 · DOI
  8. Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families, Science., 261, 921, 10.1126/science.8346443 · DOI · Paper page
  9. Cuyvers, 2016, Genetic variations underlying Alzheimer’s disease: evidence from genome-wide association studies and beyond, Lancet Neurol., 15, 857, 10.1016/S1474-4422(16)00127-7 · DOI
  10. Deroo, 2015, Chemical cross-linking/mass spectrometry maps the amyloid beta peptide binding region on both apolipoprotein E domains, ACS Chem. Biol., 10, 1010, 10.1021/cb500994j · DOI
  11. Devinsky, 2018, A cross-species approach to disorders affecting brain and behaviour, Nat. Rev. Neurol., 10.1038/s41582-018-0074-z · DOI
  12. Dodart, 2005, Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer’s disease, Proc. Natl. Acad. Sci. U. S. A., 102, 1211, 10.1073/pnas.0409072102 · DOI · Paper page
  13. van Duijn, 1994, Apolipoprotein E4 allele in a population-based study of early- onset Alzheimer’s disease, Nat. Gen., 7, 74, 10.1038/ng0594-74 · DOI
  14. Efthymiou, 2017, Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk, Mol. Neurodegener., 12, 43, 10.1186/s13024-017-0184-x · DOI · Paper page
  15. Fryer, 2003, Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice, J. Neurosci., 23, 7889, 10.1523/JNEUROSCI.23-21-07889.2003 · DOI · Paper page
  16. Garai, 2014, The binding of apolipoprotein E to oligomers and fibrils of amyloid-beta alters the kinetics of amyloid aggregation, Biochemistry, 53, 6323, 10.1021/bi5008172 · DOI · Paper page
  17. Golabek, 1995, Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid, Neurosci. Lett., 191, 79, 10.1016/0304-3940(95)11565-7 · DOI · Paper page
  18. Golabek, 1996, The interaction between apolipoprotein E and Alzheimer’s amyloid β-peptide is dependent on β-peptide conformation, J. Biol. Chem., 271, 10602, 10.1074/jbc.271.18.10602 · DOI
  19. Guerreiro, 2014, Genetics of Alzheimer’s disease, Neurotherapeutics., 11, 432, 10.1007/s13311-014-0295-9 · DOI
  20. Herline, 2018, Recent advancements toward therapeutic vaccines against Alzheimer’s disease, Expert Rev. Vaccin., 17, 707, 10.1080/14760584.2018.1500905 · DOI
  21. Heuer, 2012, Nonhuman primate models of Alzheimer-like cerebral proteopathy, Curr. Pharm. Des., 18, 1159, 10.2174/138161212799315885 · DOI · Paper page
  22. Holtzman, 2000, Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease, PNAS., 97, 2892, 10.1073/pnas.050004797 · DOI · Paper page
  23. Hori, 2015, Role of Apolipoprotein E in beta-Amyloidogenesis: isoform-specific effects on protofibril to fibril conversion of abeta in vitro and brain abeta deposition in vivo, J. Biol. Chem., 290, 15163, 10.1074/jbc.M114.622209 · DOI
  24. Hu, 2017, Recent advances in scaffold hopping, J. Med. Chem., 60, 1238, 10.1021/acs.jmedchem.6b01437 · DOI
  25. Huang, 2014, Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases, Neurobiol. Dis., 72, 3, 10.1016/j.nbd.2014.08.025 · DOI · Paper page
  26. Hudry, 2019, Opposing roles of apolipoprotein E in aging and neurodegeneration, Life Sci Alliance, 2, 10.26508/lsa.201900325 · DOI · Paper page
  27. Hyman, 1995, Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome), Proc. Natl. Acad. Sci. U. S. A., 92, 3586, 10.1073/pnas.92.8.3586 · DOI · Paper page
  28. Karch, 2014, Alzheimer’s disease genetics: from the bench to the clinic, Neuron., 83, 11, 10.1016/j.neuron.2014.05.041 · DOI · Paper page
  29. Karch, 2015, Alzheimer’s disease risk genes and mechanisms of disease pathogenesis, Biol. Psychiatry, 77, 43, 10.1016/j.biopsych.2014.05.006 · DOI · Paper page
  30. Kim, 2014, Genetic markers for diagnosis and pathogenesis of Alzheimer’s disease, Gene., 545, 185, 10.1016/j.gene.2014.05.031 · DOI
  31. Kim, 2018, Genetics of Alzheimer’s disease, Dement. Neurocogn. Disord., 17, 131, 10.12779/dnd.2018.17.4.131 · DOI
  32. Kunkle, 2019, Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing, Nat. Genet., 51, 414, 10.1038/s41588-019-0358-2 · DOI · Paper page
  33. Lane, 2018, Alzheimer’s disease, Eur. J. Neurol., 25, 59, 10.1111/ene.13439 · DOI · Paper page
  34. Laws, 2002, APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss, Mol. Psychiatry, 7, 768, 10.1038/sj.mp.4001083 · DOI
  35. Lim, 2017, APOE genotype and early beta-amyloid accumulation in older adults without dementia, Neurology, 89, 1028, 10.1212/WNL.0000000000004336 · DOI · Paper page
  36. Liu, 2011, Mapping ApoE/Abeta binding regions to guide inhibitor discovery, Mol. BioSyst., 7, 1693, 10.1039/c1mb05019b · DOI
  37. Liu, 2014, Blocking the apolipoprotein E/amyloid β-interaction in triple transgenic mice ameliorates Alzheimer’s disease related amyloid β and tau pathology, J. Neurochem., 128, 591
  38. Liu, 2017, Targeting apolipoprotein E/amyloid β binding by peptoid CPO_Aβ17-21P ameliorates Alzheimer’s disease related pathology and cognitive decline, Sci. Rep., 7, 8009, 10.1038/s41598-017-08604-8 · DOI
  39. Luo, 2010, In silico analysis of the apolipoprotein E and the amyloid beta peptide interaction: misfolding induced by frustration of the salt bridge network, PLoS Comput. Biol., 6, 10.1371/journal.pcbi.1000663 · DOI
  40. Ma, 1996, Alzheimer Aβ neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides, Neurobiol. Aging, 17, 773, 10.1016/0197-4580(96)00112-1 · DOI · Paper page
  41. Mahley, 2012, Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology, J. Med. Chem., 55, 8997, 10.1021/jm3008618 · DOI · Paper page
  42. Martins, 1995, ApoE genotypes in Australia: roles in early and late onset Alzheimer’s disease and Down’s syndrome, Neuroreport., 6, 1513, 10.1097/00001756-199507310-00012 · DOI
  43. Matsubara, 1995, Characterization of apolipoprotein J-Alzheimer’s A beta interaction, J. Biol. Chem., 270, 7563, 10.1074/jbc.270.13.7563 · DOI · Paper page
  44. Medway CW, Abdul-Hay S, Mims T, Ma L, Bisceglio G, Zou F, Pankratz S, Sando SB, Aasly JO, Barcikowska M, Siuda J, Wszolek ZK, Ross OA, Carrasquillo M, Dickson DW, Graff-Radford N, Petersen RC, Ertekin-Taner N, Morgan K, Bu G, Younkin SG. ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Mol. Neurodegener. 2014;9:11. Epub 2014/03/13. doi: https://doi.org/10.1186/1750-1326-9-11. (PubMed PMID: 24607147; PMCID: PMC3995879). · DOI · Paper page
  45. Miao, 2005, Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice, J. Neurosci., 25, 6271, 10.1523/JNEUROSCI.1306-05.2005 · DOI
  46. Morelli, 1996, Cerebrovascular amyloidosis in squirrel monkeys and rhesus monkeys: apolipoprotein E genotype, FEBS Lett., 379, 132, 10.1016/0014-5793(95)01491-8 · DOI
  47. Pimenova, 2017, Untangling genetic risk for Alzheimer’s disease, Biol. Psychiatry
  48. Pletnikova, 2018, The spectrum of preclinical Alzheimer’s disease pathology and its modulation by ApoE genotype, Neurobiol. Aging, 71, 72, 10.1016/j.neurobiolaging.2018.07.007 · DOI
  49. Potter, 2001, The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation, Neurobiol. Aging, 22, 923, 10.1016/S0197-4580(01)00308-6 · DOI
  50. Potter, 2012, Apolipoprotein E: essential catalyst of the Alzheimer amyloid cascade, Int. J. Alzheimers Dis., 489428
  51. Rabinovici, 2019, Late-onset Alzheimer disease, Continuum (Minneap Minn)., 25, 14, 10.1212/CON.0000000000000700 · DOI · Paper page
  52. Resnick, 2015, Changes in Abeta biomarkers and associations with APOE genotype in 2 longitudinal cohorts, Neurobiol. Aging, 36, 2333, 10.1016/j.neurobiolaging.2015.04.001 · DOI
  53. Roda, 2019, The role of apolipoprotein E isoforms in Alzheimer’s disease, J. Alzheimers Dis., 68, 459, 10.3233/JAD-180740 · DOI
  54. Royston, 1996, ApoE2 allele, Down’s syndrome, and dementia, Ann. N. Y. Acad. Sci., 777, 255, 10.1111/j.1749-6632.1996.tb34428.x · DOI
  55. Safieh, 2019, ApoE4: an emerging therapeutic target for Alzheimer’s disease, BMC Med., 17, 64, 10.1186/s12916-019-1299-4 · DOI · Paper page
  56. Sanan, 1994, Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3, J. Clin. Invest., 94, 860, 10.1172/JCI117407 · DOI · Paper page
  57. Saunders, 1996, Specificity, sensitivity, and predictive value of apolipoprotein- E genotyping for sporadic Alzheimer’s disease, Lancet., 348, 90, 10.1016/S0140-6736(96)01251-2 · DOI
  58. Scheltens, 2016, Alzheimer’s disease, Lancet., 388, 505, 10.1016/S0140-6736(15)01124-1 · DOI · Paper page
  59. Schmechel, 1993, Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease, Proc. Natl. Acad. Sci. U. S. A., 90, 9649, 10.1073/pnas.90.20.9649 · DOI · Paper page
  60. Schneider, 2014, Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014, J. Intern. Med., 275, 251, 10.1111/joim.12191 · DOI · Paper page
  61. Sengupta, 2016, The role of amyloid-beta oligomers in toxicity, propagation, and immunotherapy, EBioMedicine, 6, 42, 10.1016/j.ebiom.2016.03.035 · DOI · Paper page
  62. Shi, 2018, Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight, Nat. Rev. Immunol., 10.1038/s41577-018-0051-1 · DOI · Paper page
  63. Sorbi, 1995, Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer’s disease, Ann. Neurol., 38, 124, 10.1002/ana.410380120 · DOI
  64. Strittmatter, 1993, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc. Natl. Acad. Sci. U. S. A., 90, 1977, 10.1073/pnas.90.5.1977 · DOI · Paper page
  65. Strittmatter, 1993, Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease, Proc. Natl. Acad. Sci. U. S. A., 90, 8098, 10.1073/pnas.90.17.8098 · DOI · Paper page
  66. Thal, 2002, Phases of A beta-deposition in the human brain and its relevance for the development of AD, Neurology., 58, 1791, 10.1212/WNL.58.12.1791 · DOI · Paper page
  67. Tzioras, 2019, Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer’s disease, Neuropathol. Appl. Neurobiol., 45, 327, 10.1111/nan.12529 · DOI · Paper page
  68. Verghese, 2013, ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions, Proc. Natl. Acad. Sci. U. S. A., 110, 10.1073/pnas.1220484110 · DOI · Paper page
  69. Walker, 2017, The exceptional vulnerability of humans to Alzheimer’s disease, Trends Mol. Med., 23, 534, 10.1016/j.molmed.2017.04.001 · DOI
  70. Wisniewski, 1994, Acceleration of Alzheimer’s fibril formation by apolipoprotein E in vitro, Am. J. Pathol., 145, 1030
  71. Wisniewski, 2019, Future horizons in Alzheimer’s disease research, Prog. Mol. Biol. Transl. Sci., 168, 223, 10.1016/bs.pmbts.2019.08.001 · DOI
  72. Wisniewski, 1992, Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid, Neurosci. Lett., 135, 235, 10.1016/0304-3940(92)90444-C · DOI · Paper page
  73. Wisniewski, 1996, Apolipoprotein E, amyloidosis and Alzheimer’s disease, Dementia., 10, 171
  74. Wisniewski, 1994, Alzheimer’s disease and soluble Aβ, Neurobiol. Aging, 15, 143, 10.1016/0197-4580(94)90105-8 · DOI
  75. Wisniewski, 1993, Apolipoprotein E: binding to soluble Alzheimer’s beta-amyloid, Biochem. Biophys. Res. Commun., 192, 359, 10.1006/bbrc.1993.1423 · DOI · Paper page
  76. Wisniewski, 1995, The influence of apolipoprotein E isotypes on Alzheimer’s disease pathology in 40 cases of Down’s syndrome, Ann. Neurol., 37, 136, 10.1002/ana.410370128 · DOI
  77. Yang, 2011, Blocking the apolipoprotein E/amyloid β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice, J. Alzheimers Dis., 24, 269, 10.3233/JAD-2011-101401 · DOI
  78. Zalocusky, 2019, An Alzheimer’s-disease-protective APOE mutation, Nat. Med., 10.1038/s41591-019-0634-9 · DOI · Paper page
  79. Zhao, 2016, Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer’s disease mouse models, Neurobiol. Aging, 44, 159, 10.1016/j.neurobiolaging.2016.04.020 · DOI · Paper page
  80. Zhao, 2018, Apolipoprotein E, receptors, and modulation of Alzheimer’s disease, Biol. Psychiatry, 83, 347, 10.1016/j.biopsych.2017.03.003 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Wisniewski, T., & Drummond, E.
ORCID
Wisniewski, Thomas
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2020-05
Volume
138
Pages
104784
ISSN
0969-9961
DOI
10.1016/j.nbd.2020.104784
PMC
PMC7118587
Cited by
131
References
44
Language
en
Licence
Funders
  • Dementia Australia
  • National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review